GENETIC CORRECTION OF CULTURED T-CELLS FROM AN ADENOSINE DEAMINASE-DEFICIENT PATIENT - CHARACTERISTICS OF NONTRANSDUCED AND TRANSDUCED T-CELLS

被引:20
作者
BRAAKMAN, E
VANBEUSECHEM, VW
VANKRIMPEN, BA
FISCHER, A
BOLHUIS, RLH
VALERIO, D
机构
[1] TNO,INST APPL RADIOBIOL & IMMUNOL,DEPT GENE THERAPY,RIJSWIJK,NETHERLANDS
[2] HOP NECKER ENFANTS MALAD,DEPT PEDIATRY,F-75730 PARIS 15,FRANCE
关键词
D O I
10.1002/eji.1830220111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T lymphocytes derived from peripheral blood of a patient with adenosine deaminase (ADA) deficiency were expanded in vitro. The human ADA (hADA) gene was introduced into these replicating ADA- T cells with the use of an amphotropic recombinant retrovirus carrying the hADA gene. Subsequently, infected T cells were selected on the basis of their ADA expression, by exposure to a combination of the toxic agent xylofuranosyl-adenine and the specific ADA inhibitor 2'-deoxycoformycin. CD4+ and CD8+ T cells could be infected and selected with equal efficiencies. The genetically modified T cells were shown to contain intact copies of the provirus and to express normal levels of hADA. As expected, uninfected T cells from the ADA-deficient patient displayed an increased sensitivity to 2'-deoxyadenosine. Following genetic modification, however, this sensitivity was restored to normal levels in both CD4+ and CD8+ T cells. The introduction of the hADA gene into the genome of the in vitro expanded T cells did not alter their phenotype, proliferative capacity or cytotoxic potential. These characteristics were identical to those of T cells derived from healthy individuals. These findings are of critical importance for the clinical application of hADA gene-transducted T cells.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 24 条
[1]   PROSPECTS FOR HUMAN-GENE THERAPY [J].
ANDERSON, WF .
SCIENCE, 1984, 226 (4673) :401-409
[2]  
CARSON DA, 1981, J IMMUNOL, V126, P348
[3]   INVIVO EXPRESSION AND SURVIVAL OF GENE-MODIFIED LYMPHOCYTES-T IN RHESUS-MONKEYS [J].
CULVER, KW ;
MORGAN, RA ;
OSBORNE, WRA ;
LEE, RT ;
LENSCHOW, D ;
ABLE, C ;
CORNETTA, K ;
ANDERSON, WF ;
BLAESE, RM .
HUMAN GENE THERAPY, 1990, 1 (04) :399-410
[4]   SUPPRESSION OF LEUKEMIA-VIRUS PATHOGENICITY BY POLYOMA-VIRUS ENHANCERS [J].
DAVIS, B ;
LINNEY, E ;
FAN, H .
NATURE, 1985, 314 (6011) :550-553
[5]   AN INVIVO MODEL OF SOMATIC-CELL GENE-THERAPY FOR HUMAN SEVERE COMBINED IMMUNODEFICIENCY [J].
FERRARI, G ;
ROSSINI, S ;
GIAVAZZI, R ;
MAGGIONI, D ;
NOBILI, N ;
SOLDATI, M ;
UNGERS, G ;
MAVILIO, F ;
GILBOA, E ;
BORDIGNON, C .
SCIENCE, 1991, 251 (4999) :1363-1366
[6]  
GIBLETT ER, 1972, LANCET, V2, P1067
[7]  
GOEDEGEBUURE S P, 1989, Biotherapy (Dordrecht), V1, P73, DOI 10.1007/BF02170137
[8]   TREATMENT OF ADENOSINE-DEAMINASE DEFICIENCY WITH POLYETHYLENE-GLYCOL MODIFIED ADENOSINE-DEAMINASE [J].
HERSHFIELD, MS ;
BUCKLEY, RH ;
GREENBERG, ML ;
MELTON, AL ;
SCHIFF, R ;
HATEM, C ;
KURTZBERG, J ;
MARKERT, ML ;
KOBAYASHI, RH ;
KOBAYASHI, AL ;
ABUCHOWSKI, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (10) :589-596
[9]  
Hirschhorn R, 1983, Birth Defects Orig Artic Ser, V19, P73
[10]   CORRECTION OF ADENOSINE-DEAMINASE DEFICIENCY IN CULTURED HUMAN T-CELLS AND B-CELLS BY RETROVIRUS-MEDIATED GENE-TRANSFER [J].
KANTOFF, PW ;
KOHN, DB ;
MITSUYA, H ;
ARMENTANO, D ;
SIEBERG, M ;
ZWIEBEL, JA ;
EGLITIS, MA ;
MCLACHLIN, JR ;
WIGINTON, DA ;
HUTTON, JJ ;
HOROWITZ, SD ;
GILBOA, E ;
BLAESE, RM ;
ANDERSON, WF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (17) :6563-6567